Close
What would you like to look for?
Site search
30 April 2017

INOFEA AG in Basel, a company developing and commercializing a highly innovative nanotechnology platform to shield sensitive enzymes, successfully closed a financing round with contributions from returning as well as new private investors. INOFEA is a spin-out from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW).

VISCHER with Dr. Matthias Staehelin (Partner) and Sebastian Flückiger (Associate), both Corporate, advise INOFEA.

Author